Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer

Table 2

Subgroup analyses.

	Factors	No. of studies	No. of patients	Effects model	HR (95% CI)		Heterogeneity
							OS	Overall	10	3619	Random	1.777 (1.328-2.376)	<0.001	84.90%	0
Ethnicity
Europe	1	289		1.370 (1.030-1.820)	<0.001
Asia	9	3330	Random	1.835 (1.342-2.509)	<0.001	84.40%		0
Treatment
No surgery	4	706	Fixed	1.626 (1.357-1.947)	<0.001	46.90%		0.13
With surgery	5	2913	Fixed	2.244 (1.971-2.555)	<0.001	89.10%		0
Cut-off
≤500	4	2092	Fixed	2.895 (2.465-3.399)	<0.001	82.40%		0.001
>500	5	1303	Fixed	1.529 (1.326-1.764)	<0.001	47.60%		0.106
Sample size
≤200	3	295	Fixed	1.658 (1.280-2.147)	<0.001	0.00%		0.593
>200	7	3324	Fixed	2.089 (1.862-2.345)	<0.001	89.20%		0
PFS	Overall	8	3155	Random	1.658 (1.189-2.311)	<0.01	90.20%	0

CI: confidence interval; HR: hazard ratio; OS: overall survival; PFS: progression-free survival.